Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
124 hedge funds and large institutions have $307M invested in Achillion Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 45 increasing their positions, 34 reducing their positions, and 17 closing their positions.
182% more call options, than puts
Call options by funds: $426K | Put options by funds: $151K
32% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 34
2% less funds holding
Funds holding: 127 → 124 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
26% less capital invested
Capital invested by funds: $415M → $307M (-$108M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.15M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$3.06M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.89M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$866K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$829K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.38M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.08M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.06M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.47M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$3.11M |
ACHN Hedge Fund Activity: Q2 2018 in Review
124 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2018, worth a combined $307M — down 26% from $415M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ACHN and 14 opened new positions — a net loss of 3 holders — while 34 trimmed existing stakes and 45 added.
The largest buyer was Citadel Advisors, adding an estimated $6.15M. The largest seller was Fidelity Investments, exiting entirely with an estimated $5.38M sold.
- 124 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2018, down from 127 in Q1 2018.
- Funds reported $307M of Achillion Pharmaceuticals stock for Q2 2018, down 26% quarter-over-quarter.
- 14 funds opened new Achillion Pharmaceuticals positions in Q2 2018 and 17 closed out, a net change of -3 holders.
- The largest Achillion Pharmaceuticals buyer in Q2 2018 was Citadel Advisors, an estimated $6.15M added.
- The largest Achillion Pharmaceuticals seller in Q2 2018 was Fidelity Investments, an estimated $5.38M sold.
Based on aggregated 13F filings for Q2 2018.